Biodegradable nanoparticles with sustained release of functional siRNA in skin.

A key challenge in developing RNAi-based therapeutics is efficient delivery of functional short interfering RNA (siRNA) to target cells. To address this need, we have used a supercritical CO(2) process to incorporate siRNA in biodegradable polymer nanoparticles (NPs) for in vivo sustained release. By this means we have obtained complete encapsulation of the siRNA with minimal initial burst effect from the surface of the NPs. The slow release of a fluorescently labeled siRNA mimic (siGLO Red) was observed for up to 80 days in vivo after intradermal injection into mouse footpads. In vivo gene silencing experiments were also performed, showing reduction of GFP signal in the epidermis of a reporter transgenic mouse model, which demonstrates that the siRNA retained activity following release from the polymer NPs.

[1]  R. Zare,et al.  Nanoparticle formation of organic compounds with retained biological activity. , 2010, Journal of pharmaceutical sciences.

[2]  R. Hickerson,et al.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  G. Kino,et al.  siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model , 2009, Gene Therapy.

[4]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[5]  D. Leake,et al.  Stability study of unmodified siRNA and relevance to clinical use. , 2008, Oligonucleotides.

[6]  R. Zare,et al.  Sustained release of drugs dispersed in polymer nanoparticles. , 2008, Angewandte Chemie.

[7]  E. Lane,et al.  Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. , 2008, Journal of dermatological science.

[8]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[9]  D. Leake,et al.  Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. , 2008, The Journal of investigative dermatology.

[10]  A. Akinc,et al.  Delivering silence: advancements in developing siRNA therapeutics. , 2008, Current opinion in drug discovery & development.

[11]  A. D. Fougerolles Delivery vehicles for small interfering RNA in vivo. , 2008 .

[12]  Shubiao Zhang,et al.  Cationic lipids and polymers mediated vectors for delivery of siRNA. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[14]  F. He,et al.  Cationic lipids enhance siRNA-mediated interferon response in mice. , 2005, Biochemical and biophysical research communications.

[15]  D. Sørensen,et al.  Cationic liposome-mediated delivery of siRNAs in adult mice. , 2003, Biochemical and biophysical research communications.

[16]  E. Reverchon,et al.  Particle Design Using Supercritical Fluids , 2003 .

[17]  Ž. Knez,et al.  Particles formation and particle design using supercritical fluids , 2003 .

[18]  Mouldy Sioud,et al.  Gene silencing by systemic delivery of synthetic siRNAs in adult mice. , 2003, Journal of molecular biology.

[19]  Jennifer Jung,et al.  Particle design using supercritical fluids: Literature and patent survey , 2001 .

[20]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[21]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.